Evenity gets first ever approval, in Japan

9 January 2019

The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted a marketing authorization for Evenity (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.

Belgian drugmaker UCB (Euronext Brussels: UCB) and US biotech Amgen (Nasdaq: AMGN) are co-developing romosozumab worldwide, with development in Japan being led by Amgen Astellas BioPharma (AABP), a joint venture between Amgen and Japan’s Astellas Pharma (TYO: 4503.

“With one of the longest life expectancy rates in the world Japan is a country of longevity, but this means that the rate of osteoporosis will increase, leaving many people at high risk for fracture due to the condition,” said Dr Pascale Richetta, head of bone and executive vice president, UCB. “We are proud that romosozumab is now approved as a new treatment to help address this important public health issue and help people with their osteoporosis.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK